4'-O-Methylpyridoxine

Name: 4'-O-Methylpyridoxine
Brand: MedChemExpress
SKU: HY-N8157
Rating: 4.5 (1 reviews)

Cat. No.: HY-N8157 Purity: 99.92%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

4'-O-Methylpyridoxine is an orally active antivitamin B6 compound found in Ginkgo biloba seeds and leaves. 4'-O-Methylpyridoxine inhibits pyridoxal kinase. 4'-O-Methylpyridoxine reduces brain pyridoxal-5'-phosphate (PLP) levels, decreases gamma-aminobutyric acid/glutamate (GABA/Glu) ratio. 4'-O-Methylpyridoxine increases plasma levels of pyridoxal-5'-phosphate and pyridoxal. 4'-O-Methylpyridoxine induces hyperactivity, convulsions, pathological tissue changes, organ damage in rodent brain and heart.

For research use only. We do not sell to patients.

4'-O-Methylpyridoxine Chemical Structure

CAS No. : 1464-33-1

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE 4'-O-Methylpyridoxine

•Dev Cell. 2025 Nov 27:S1534-5807(25)00691-4. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

4'-O-Methylpyridoxine inhibits pyridoxal kinase^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

4'-O-Methylpyridoxine (5-80 nmol; i.c.v.; single dose) induces dose-dependent hyperactivity and seizures in male ddY mice^[1].
4'-O-Methylpyridoxine (10-50 mg/kg; i.g.; daily; 15 days) causes pathological changes in the brain and heart tissues of rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	ddY mice (male, 4-5-week-old, mean body weight 29.2 ± 3.1 g, intrathecal administration-induced neurological dysfunction)^[1]
Dosage:	5 nmol; 10 nmol; 20 nmol; 40 nmol; 80 nmol; 0.39 mg/kg (lowest seizure-inducing dose/body weight ratio)
Administration:	i.c.v.; single dose
Result:	Induced 0% seizure incidence at 5 nmol, 10 nmol and 20 nmol, 11% at 40 nmol, 20% at 80 nmol. Showed lowest seizure-inducing dose/body weight ratio of 0.39 mg/kg (1.79 nmol/kg). Caused significantly lower brain PLP concentration, brain total vitamin B6 (PLP+PL) concentration, and brain GABA/Glu ratio in hyperactive mice compared to control mice.

Animal Model:	Sprague Dawley (SD) (male, 8-week-old, 210 ± 10 g)^[2]
Dosage:	10 mg/kg; 30 mg/kg; 50 mg/kg
Administration:	i.g.; daily; 15 days
Result:	Showed no significant effect on body weight, food/water intake, or organ coefficients. Caused pathological changes in brain (apoptotic hippocampal pyramidal cells with nuclear pyknosis) and heart (mild vacuolar degeneration of left ventricular myocardial cells, mild interstitial vascular congestion) tissues at 50 mg/kg. Significantly increased plasma levels of pyridoxal-5'-phosphate (PLP), pyridoxal (PL), total vitamin B6 (TVB6), and pyridoxine (PN) at 10 mg/kg and 30 mg/kg; significantly increased plasma pyridoxamine (PM) levels at 10 mg/kg; showed no significant difference in plasma PLP, PL, and TVB6 levels from controls at 50 mg/kg, while significantly elevated PN levels at all doses. Significantly increased plasma protein, free fatty acid, creatinine, aspartate aminotransferase (AST), and creatine kinase (CK) levels; decreased plasma triglyceride and uric acid levels at all doses. Significantly increased plasma alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) levels at 30 mg/kg and 50 mg/kg; significantly decreased plasma hemoglobin levels and increased plasma cholesterol levels at 50 mg/kg. Significantly increased plasma malondialdehyde (MDA) and glutathione peroxidase (GSH-Px) levels, and decreased total antioxidant capacity (T-AOC) and glutathione (GSH) levels at 50 mg/kg; significantly decreased plasma GSH levels at 30 mg/kg; showed no significant changes in superoxide dismutase (SOD) levels at any dose.

Molecular Weight

183.20

Formula

C₉H₁₃NO₃

CAS No.

1464-33-1

Appearance

Solid

Color

White to yellow

SMILES

OCC1=C(COC)C(O)=C(C)N=C1

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (545.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.4585 mL	27.2926 mL	54.5852 mL
5 mM	1.0917 mL	5.4585 mL	10.9170 mL
10 mM	0.5459 mL	2.7293 mL	5.4585 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (13.65 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (13.65 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (13.65 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.92%

Select Batch:

Data Sheet (280 KB) SDS (393 KB)

COA (250 KB) HNMR (398 KB) RP-HPLC (205 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Sado T, et al. Direct Evidence that 4'-O-methylpyridoxine Induces Hyperactivity and Convulsions due to Pyridoxal Phosphate Deficiency in the Brain[J]. THE SHINSHU MEDICAL JOURNAL, 2024, 72(3): 159-167.

[2]. Zhu JP, et al. In vivo toxicity assessment of 4'-O-methylpyridoxine from Ginkgo biloba seeds: Growth, hematology, metabolism, and oxidative parameters. Toxicon. 2021;201:66-73. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.4585 mL	27.2926 mL	54.5852 mL	136.4629 mL
	5 mM	1.0917 mL	5.4585 mL	10.9170 mL	27.2926 mL
	10 mM	0.5459 mL	2.7293 mL	5.4585 mL	13.6463 mL
	15 mM	0.3639 mL	1.8195 mL	3.6390 mL	9.0975 mL
	20 mM	0.2729 mL	1.3646 mL	2.7293 mL	6.8231 mL
	25 mM	0.2183 mL	1.0917 mL	2.1834 mL	5.4585 mL
	30 mM	0.1820 mL	0.9098 mL	1.8195 mL	4.5488 mL
	40 mM	0.1365 mL	0.6823 mL	1.3646 mL	3.4116 mL
	50 mM	0.1092 mL	0.5459 mL	1.0917 mL	2.7293 mL
	60 mM	0.0910 mL	0.4549 mL	0.9098 mL	2.2744 mL
	80 mM	0.0682 mL	0.3412 mL	0.6823 mL	1.7058 mL
	100 mM	0.0546 mL	0.2729 mL	0.5459 mL	1.3646 mL